Objective:To analyze the impact of nursing interventions based on quantitative assessment using the Kano model on the quality of rehabilitation in patients with early-stage ovarian cancer following laparoscopic radica...Objective:To analyze the impact of nursing interventions based on quantitative assessment using the Kano model on the quality of rehabilitation in patients with early-stage ovarian cancer following laparoscopic radical surgery.Methods:A prospective clinical study was conducted involving 96 patients with newly diagnosed early-stage ovarian cancer who underwent laparoscopic radical surgery from December 2023 to December 2025.Patients were randomly assigned to groups using a random number table method before surgery.After surgery,the control group(n=48)received routine quantitative assessment nursing interventions,while the observation group(n=48)received nursing interventions based on quantitative assessment using the Kano model.Both groups received continuous nursing care until discharge.Differences between the groups were compared in terms of negative emotions,quality of life scores before and after postoperative intervention,postoperative recovery indicators,and nursing satisfaction evaluations on the day of discharge.Results:After intervention,the observation group had lower scores on the Self-Rating Anxiety Scale(SAS)and Self-Rating Depression Scale(SDS),as well as shorter recovery times for gastrointestinal function and food intake,and a shorter hospital stay compared to the control group.Additionally,the observation group had higher scores on the Quality-of-Life Instrument for Cancer Patients-Ovarian Cancer(QLICP-OV)than the control group,with statistically significant differences(p<0.05).The overall satisfaction with nursing care in the observation group was also higher than that in the control group,with a statistically significant difference(p<0.05).Conclusion:Implementing quantitative evaluation nursing interventions based on the Kano model for patients with early-stage ovarian cancer after laparoscopic radical surgery can,by addressing their postoperative basic health,disease awareness,and other intervention content needs to a comprehensive degree,actively promote postoperative recovery and improve their mental health and quality of life.展开更多
Objective:Ovarian cancer(OC)ranks among the leading causes of mortality among the female cancers worldwide.Numerous studies have explored the development and progression of OC at multiple genetic regulatory levels.How...Objective:Ovarian cancer(OC)ranks among the leading causes of mortality among the female cancers worldwide.Numerous studies have explored the development and progression of OC at multiple genetic regulatory levels.However,relatively few studies have explored the impact of post-translational modifications(PTM)on OC progression,which is essential for uncovering new therapeutic targets.This study aimed to systematically identify the key PTM types involved in OCprogression,and to explore and evaluate their translational potential as therapeutic targets.Methods:First,we utilized multiple general PTM antibodies to compare gross PTM levels between normal ovarian and OC tissues from clinical females.After identifying lactylation as the PTM with the most significant differences,we selected representative samples for label-free mass spectrometry to identify specific lactylation sites.Next,we transfected A2780(OC)cells with either wild-type(WT)or mutant(K192A[Q])poly(ADP-ribose)polymerase 1(PARP1)conjugated to enhanced green fluorescent protein(EGFP)with a StrepⅡpeptide tag and assessed various cellular indexes related to cell proliferation(clonogenicity assay),migration(scratch wound healing assay),and reactive oxygen species levels.Results:Pan-lactylation was significantly upregulated in clinical OC samples,with PARP1 lactylation at K192 being one of the most common modifications.The growth and migration of A2780 cells were markedly suppressed by overexpressing PARP1-WT but not mutant PARP1.Overexpressing PARP1 significantly downregulated the phosphorylation of extracellular signal-regulated kinases 1/2(ERK1/2).Conclusion:This study uncovered a novel PTM of PARP1 in OC,lactylation,and demonstrated that lactylation at K192 is crucial in regulating OC cell growth and migration via the ERK1/2 pathway.Further investigations are required to elucidate the broader functional implications of PARP1 lactylation and its therapeutic potential.展开更多
Objectives:Monitoring of Cancer Antigen 125(CA125)during ovarian cancer(OC)maintenance treatment with poly(ADP-ribose)polymerase inhibitors(PARPis)may be insufficient when using Gynecologic Cancer Intergroup(GCIG)bioc...Objectives:Monitoring of Cancer Antigen 125(CA125)during ovarian cancer(OC)maintenance treatment with poly(ADP-ribose)polymerase inhibitors(PARPis)may be insufficient when using Gynecologic Cancer Intergroup(GCIG)biochemical progression criteria.This study aimed to evaluate the usefulness of CA125 monitoring in detecting OC recurrence during PARPis maintenance treatment.Methods:This multicenter retrospective cohort study included patients with primary OC who achieved complete or partial response after first-line platinum-based chemotherapy followed by PARPis maintenance treatment.Progressionwas defined using Response EvaluationCriteria in Solid Tumors(RECIST)and GCIG biochemical criteria.New biochemical progression definitions,based on CA125 nadir determined using receiver operating characteristic(ROC)curve analysis,were proposed.Concordance between radiological and biochemical progression was assessed.Results:Of 142 patients,progression was detected in 54(38.03%)and 29(20.42%)using RECIST and GCIG criteria,respectively.The sensitivity,specificity,positive predictive value(PPV),and negative predictive value(NPV)of the GCIG criteria were 53.70%[95%confidence interval(CI):39.61%–67.38%],100.00%[95%CI:95.91%–100.00%],100.00%[95%CI:88.10%–100.00%]and 77.88%[95%CI:72.54%–82.43%],respectively.A cut-off of 1.59×nadir achieved 88.90%sensitivity and 87.20%specificity[Area Under Curve(AUC):91.10%,95%CI:84.70%–97.40%]with a false positive rate(FPR)of 12.67%.Defining biochemical progression as an increase in CA125 of≥3×nadir achieved sensitivity,specificity,PPV,NPV,and FPR of 79.63%[95%CI:66.47%–89.37%],98.86%[95%CI:93.83%–99.97%],97.73%[95%CI:85.91%–99.67%],88.78%[95%CI:82.35%–93.06%],and 1.14%,respectively.Diagnostic accuracy was higher using the≥3×nadir criterion compared with GCIG definition(91.55%vs.82.39%).Conclusion:GCIG biochemical progression criteria during PARPis maintenance treatment after first-line chemotherapymissed 46.3%of progressing patients.Anewcriterion—CA125≥3×nadir—improves sensitivity and NPV,while maintaining high specificity,offering a simple and practical approach for clinical implementation.展开更多
BACKGROUND Mitochondrial genes are involved in tumor metabolism in ovarian cancer(OC)and affect immune cell infiltration and treatment responses.AIM To predict prognosis and immunotherapy response in patients diagnose...BACKGROUND Mitochondrial genes are involved in tumor metabolism in ovarian cancer(OC)and affect immune cell infiltration and treatment responses.AIM To predict prognosis and immunotherapy response in patients diagnosed with OC using mitochondrial genes and neural networks.METHODS Prognosis,immunotherapy efficacy,and next-generation sequencing data of patients with OC were downloaded from The Cancer Genome Atlas and Gene Expression Omnibus.Mitochondrial genes were sourced from the MitoCarta3.0 database.The discovery cohort for model construction was created from 70% of the patients,whereas the remaining 30% constituted the validation cohort.Using the expression of mitochondrial genes as the predictor variable and based on neural network algorithm,the overall survival time and immunotherapy efficacy(complete or partial response)of patients were predicted.RESULTS In total,375 patients with OC were included to construct the prognostic model,and 26 patients were included to construct the immune efficacy model.The average area under the receiver operating characteristic curve of the prognostic model was 0.7268[95% confidence interval(CI):0.7258-0.7278]in the discovery cohort and 0.6475(95%CI:0.6466-0.6484)in the validation cohort.The average area under the receiver operating characteristic curve of the immunotherapy efficacy model was 0.9444(95%CI:0.8333-1.0000)in the discovery cohort and 0.9167(95%CI:0.6667-1.0000)in the validation cohort.CONCLUSION The application of mitochondrial genes and neural networks has the potential to predict prognosis and immunotherapy response in patients with OC,providing valuable insights into personalized treatment strategies.展开更多
Paclitaxel is one of the commonly used drugs in postoperative chemotherapy for ovarian cancer patients. However, affected by drug dosage and individual differences in the course of medication, patients will have diffe...Paclitaxel is one of the commonly used drugs in postoperative chemotherapy for ovarian cancer patients. However, affected by drug dosage and individual differences in the course of medication, patients will have different degrees of adverse reactions, which will cause damage to the patient’s body once they occur. This paper retrospectively analyzed the clinical data of patients with severe allergic reactions such as fecal incontinence and numbness of hands and feet caused by the use of paclitaxel liposome during postoperative chemotherapy in a case of ovarian cancer admitted to our hospital. The causes and corresponding treatment measures were analyzed, in order to provide the reference for medical staff to take effective countermeasures in advance in the future.展开更多
Following the publication,concerns have been raised about a number of figures in this article.The western blots in this article were presented with atypical,unusually shaped and possibly anomalous protein bands in man...Following the publication,concerns have been raised about a number of figures in this article.The western blots in this article were presented with atypical,unusually shaped and possibly anomalous protein bands in many cases.展开更多
Ovarian cancer ranks as the deadliest malignancy among female reproductive system cancers,posing a significant threat to women’s health.Around seven out of ten patients are diagnosed only after reaching progressive d...Ovarian cancer ranks as the deadliest malignancy among female reproductive system cancers,posing a significant threat to women’s health.Around seven out of ten patients are diagnosed only after reaching progressive disease phases,a phenomenon closely linked to three key factors:the disease’s hidden onset location,lack of early symptoms,and absence of reliable early diagnostic methods.Therefore,identifying early diagnostic biomarkers and therapeutic targets is critical.Exosomes participate in various phases of ovarian tumorigenesis,including transforming normal cells into cancerous cells,immune regulation,invasion,metastasis,drug resistance,and angiogenesis,making them promising biomarkers for early ovarian cancer detection.This review summarizes current research on exosomal long non-coding RNAs(lncRNAs),miRNAs,and related proteins in ovarian cancer diagnosis.Exosome-based biomarkers have shown potential advantages,including high sensitivity,specificity,stability,and non-invasive accessibility.The study concludes that while exosomes hold significant diagnostic potential for ovarian cancer,additional investigations are required to standardize detection methods,validate clinical applicability,and elucidate underlying molecular mechanisms.展开更多
Ovarian cancer(OC),a highly lethal gynaecological malignancy,is often diagnosed at advanced stages,resulting in a poor prognosis.Sialylation,an important form of glycosylation,significantly contributes to the progress...Ovarian cancer(OC),a highly lethal gynaecological malignancy,is often diagnosed at advanced stages,resulting in a poor prognosis.Sialylation,an important form of glycosylation,significantly contributes to the progression of various solid tumours,including OC.Aberrant sialylation promotes tumour progression and metastasis by altering the structure and function of glycoproteins.Although its role in several solid tumours is well documented,the role of abnormal sialylation in OC and its potential as a therapeutic target remain poorly understood.This review highlights sialylation as a key regulator of the progression,metastasis,and drug resistance of OC.A deeper understanding of altered sialylation can contribute to the identification of novel therapeutic strategies for OC.展开更多
Ovarian cancer poses a significant threat to women's health,necessitating effective therapeutic strategies.Emd-D,an emodin derivative,demonstrates enhanced pharmaceutical properties and bioavailability.In this stu...Ovarian cancer poses a significant threat to women's health,necessitating effective therapeutic strategies.Emd-D,an emodin derivative,demonstrates enhanced pharmaceutical properties and bioavailability.In this study,Cell Counting Kit 8(CCK8)assays and Ki-67 staining revealed dose-dependent inhibition of cell proliferation by Emd-D.Migration and invasion experiments confirmed its inhibitory effects on OVHM cells,while flow cytometry analysis demonstrated Emd-D-induced apoptosis.Mechanistic investigations elucidated that Emd-D functions as an inhibitor by directly binding to the glycolysis-related enzyme PFKFB4.This was corroborated by alterations in intracellular lactate and pyruvate levels,as well as glucose transporter 1(GLUT1)and hexokinase 2(HK2)expression.PFKFB4 overexpression experiments further supported the dependence of Emd-D on PFKFB4-mediated glycolysis and SRC3/mTORC1 pathway-associated apoptosis.In vivo experiments exhibited reduced xenograft tumor sizes upon Emd-D treatment,accompanied by suppressed glycolysis and increased expression of Bax/Bcl-2 apoptotic proteins within the tumors.In conclusion,our findings demonstrate Emd-D's potential as an anti-ovarian cancer agent through inhibition of the PFKFB4-dependent glycolysis pathway and induction of apoptosis.These results provide a foundation for further exploration of Emd-D as a promising drug candidate for ovarian cancer treatment.展开更多
BACKGROUND Substantial clinical evidence supports the efficacy of cognitive behavioral therapy(CBT)for various diseases,particularly in oncology.However,the true impact of CBT interventions on cancer-related fatigue a...BACKGROUND Substantial clinical evidence supports the efficacy of cognitive behavioral therapy(CBT)for various diseases,particularly in oncology.However,the true impact of CBT interventions on cancer-related fatigue and mental health in patients with ovarian cancer remains unknown.AIM To evaluate the effects of CBT on fatigue,anxiety,depression and quality of life in patients with ovarian cancer.METHODS Randomized controlled trials(RCTs)on CBT for patients with ovarian cancer were searched in the PubMed,EMBASE,Web of Science and Cochrane Library databases.According to the preferred reporting items for systematic reviews and meta-analyses statement,we formulated the inclusion and exclusion criteria,strictly screened the literatures,extracted data and performed a meta-analysis.RESULTS Six RCTs with 332 ovarian cancer patients were included.Compared with the control group,cancer fatigue[mean difference(MD)=-0.98,95%confidence interval(CI):-1.47 to-0.50],anxiety[standardized mean difference(SMD)=-0.64,95%CI:-0.91 to-0.36]and depression levels(SMD=-0.41,95%CI:-0.76 to-0.06)of the patients in the experimental group reduced after CBT intervention.Quality of life(MD=1.28,95%CI:0.65 to 1.90)and sleep quality(MD=-0.49,95%CI:-0.66 to-0.33)of the patients improved,and the differences between the groups were statistically significant(P<0.01).The quality evaluation results suggested that the quality of the included RCTs was low.The meta-regression results showed that patient age and nurse guidance affected treatment outcomes,especially anxiety,whereas the specific method of CBT had a non-significant effect.CONCLUSION CBT effectively improves mental status and cancer-related fatigue in patients with ovarian cancer undergoing chemotherapy.Future research should prioritize adequately powered RCTs with standardized outcome measures and longitudinal designs to establish sustained efficacy.展开更多
c-Kit (CD117) is a type IIIa receptor tyrosine kinase (RTK) that plays a key role in regulating the normal physiological processes of cells. In addition, the activation of c-Kit activates the tyrosine kinase signal tr...c-Kit (CD117) is a type IIIa receptor tyrosine kinase (RTK) that plays a key role in regulating the normal physiological processes of cells. In addition, the activation of c-Kit activates the tyrosine kinase signal transduction pathway, which is closely related to the occurrence and development of gynecological tumors, especially ovarian cancer. This article reviews the mechanisms of platinum resistance in ovarian cancer and the research progress of c-Kit in ovarian cancer.展开更多
Ovarian cancer remains a leading cause of gynecological cancer mortality1,and patients with advanced stage ovarian cancer frequently develop malignant ascites that foster immunosuppressive microenvironments and therap...Ovarian cancer remains a leading cause of gynecological cancer mortality1,and patients with advanced stage ovarian cancer frequently develop malignant ascites that foster immunosuppressive microenvironments and therapeutic resistance2,3.Although ascites have traditionally been considered detrimental,we report a paradoxical role in which they enhance the cytotoxicity ofγδT cells—a unique T cell subset that can be allogenically transferred for cancer treatment4,5—toward ovarian cancer.展开更多
BACKGROUND Ovarian carcinoma has the highest mortality rate among all gynecological cancers.Several reproductive and hormonal risk factors,including early menarche,late menopause,limited use of oral contraceptives,and...BACKGROUND Ovarian carcinoma has the highest mortality rate among all gynecological cancers.Several reproductive and hormonal risk factors,including early menarche,late menopause,limited use of oral contraceptives,and a low pregnancy rate,have been identified as contributors to the increased susceptibility to ovarian cancer.Advancements in cancer therapy over the past century,including the emergence of precision oncology,underscore the importance of early detection and tailored interventions,factors particularly critical in ovarian cancer,where late-stage diagnosis remains a persistent barrier to survival.This challenge is compounded by the lack of a universally endorsed screening program,resulting in late-stage identification and widespread metastasis.AIM To evaluate demographic differences in ovarian cancer-related mortality from 1999 to 2020 among adult females aged≥25 years within the United States.METHODS Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database was used to collect de-identified death certificate data for malignant neoplasm of the ovaries related deaths in female adults aged 25 years and older from the year 1999 to 2020.Crude mortality rates and age-adjusted mortality rates(AAMRs)per 100000 people were calculated.Join point regression program was used to assess annual percent changes in mortality trends,with statistical significance set at P value<0.05.RESULTS Between 1999 and 2020,337619 deaths due to ovarian cancer occurred among United States females aged 25 to>85.The AAMR decreased from 14.62 in 1999 to 10.15 in 2020,with significant declines across various demographics.The AAMRs were highest among non-Hispanic White women,i.e.,13.53.Based on region,they were the highest in the Northeast(13.06)and Midwest(12.94).The steepest decline was observed in metropolitan areas as compared to nonmetropolitan ones.The study highlights significant progress in reducing ovarian cancer mortality across age,race/ethnicity,and geographic regions during this period.CONCLUSION The mortality trends for ovarian carcinoma patients showed an overall decrease,with the highest mortality rates observed among older individuals(65 to>85 years)and non-Hispanic Whites.These disparities underscore the need for equitable healthcare access and targeted policy interventions.展开更多
BACKGROUND Ovarian cancer patients often face complex treatment processes and psychological challenges,with different treatment modalities potentially affecting patients’psychological adjustment abilities.AIM To expl...BACKGROUND Ovarian cancer patients often face complex treatment processes and psychological challenges,with different treatment modalities potentially affecting patients’psychological adjustment abilities.AIM To explore the differences in psychological adjustment patterns among ovarian cancer patients receiving surgery,chemotherapy,targeted therapy,and combined therapy,and to analyze their relationship with clinical outcomes.METHODS A retrospective analysis was conducted on the clinical data of 286 ovarian cancer patients who received different treatment modalities from January 2020 to December 2023.Patients were divided into surgery group(n=78),chemotherapy group(n=65),targeted therapy group(n=61),and combined therapy group(n=82).The Self-Rating Anxiety Scale,Self-Rating Depression Scale,and Psychological Adjustment to Cancer Scale were used to assess psychological status,while quality of life,treatment adherence,and two-year survival rate data were collected.Some patients(n=76)received systematic psychological intervention,and the intervention effects were evaluated.RESULTS Patients in the combined therapy group had significantly higher Self-Rating Anxiety Scale(56.3±7.2)and Self-Rating Depression Scale(58.4±6.9)scores than other groups,with the highest incidence of anxiety(58.5%)and depression(62.2%);the targeted therapy group scored highest in the positive coping dimension(28.5±3.6)and had the lowest incidence of anxiety and depression(29.5%/31.1%).Logistic regression analysis showed that positive coping(odds ratio=2.86,95%confidence interval:1.75-4.68)and utilization of social support(odds ratio=2.13,95%confidence interval:1.42-3.56)were protective factors for good treatment adherence.Longitudinal assessment showed that although all patients experienced increased anxiety and depression symptoms at 3 months of treatment,the targeted therapy group and surgery group showed significant improvement at 6 months(P<0.05),while the combined therapy group showed no significant improvement.Psychological intervention effectively improved patients’treatment adherence(by 22.7%)and quality of life(by 15.6 points),with the best effect in the combined therapy group(anxiety incidence decreased by 30.5%,P<0.001).CONCLUSION Different treatment modalities significantly affect the psychological adjustment abilities of ovarian cancer patients,with combined therapy patients facing greater psychological challenges,while targeted therapy patients exhibit healthier psychological adjustment patterns.展开更多
Ovarian cancer(OC)remains one of the most lethal gynecological malignancies globally.Despite the implementation of various medical imaging approaches for OC screening,achieving accurate differential diagnosis of ovari...Ovarian cancer(OC)remains one of the most lethal gynecological malignancies globally.Despite the implementation of various medical imaging approaches for OC screening,achieving accurate differential diagnosis of ovarian tumors continues to pose significant challenges due to variability in image performance,resulting in a lack of objectivity that relies heavily on the expertise of medical professionals.This challenge can be addressed through the emergence and advancement of radiomics,which enables high-throughput extraction of valuable information from conventional medical images.Furthermore,radiomics can integrate with genomics,a novel approach termed radiogenomics,which allows for a more comprehensive,precise,and personalized assessment of tumor biological features.In this review,we present an extensive overview of the application of radiomics and radiogenomics in diagnosing and predicting ovarian tumors.The findings indicate that artificial intelligence methods based on imaging can accurately differentiate between benign and malignant ovarian tumors,as well as classify their subtypes.Moreover,these methods are effective in forecasting survival rates,treatment outcomes,metastasis risk,and recurrence for patients with OC.It is anticipated that these advancements will function as decision-support tools for managing OC while contributing to the advancement of precision medicine.展开更多
Ovarian cancer is a prevalent gynecological malignancy with high mortality and low survival rates.The absence of specific symptoms in early stages often leads to late-stage diagnoses.Standard treatment typically inclu...Ovarian cancer is a prevalent gynecological malignancy with high mortality and low survival rates.The absence of specific symptoms in early stages often leads to late-stage diagnoses.Standard treatment typically includes surgery followed by platinum and paclitaxel chemotherapy.Exosomes,nanoscale vesicles released by various cell types,are key in intercellular communication,carrying biologically active molecules like proteins,lipids,enzymes,mRNA,and miRNAs.They are involved in tumor microenvironment remodeling,angiogenesis,metastasis,and chemoresistance in ovarian cancer.Emerging research highlights exosomes as drug carriers and therapeutic targets to suppress anti-tumor immune responses.Surface-enhanced Raman scattering(SERS)enables multiplexed,sensitive,and rapid detection of exosome surface proteins,offering advantages such as low background noise,no photobleaching,robustness,and high sensitivity over other detection methods.This review explores the relationship between exosomes and chemoresistance in ovarian cancer,examining the mechanisms by which exosomes contribute to drug resistance and their clinical implications.The goal is to provide new insights into chemoresistance mechanisms,improve diagnosis and intervention strategies,and enhance chemotherapy sensitivity in clinical treatments.In addition,the prospects of exosomes as drug carriers to resist chemical resistance and improve the survival of ovarian cancer patients are summarized.This article emphasizes the role of SERS in detecting ovarian cancer exosomes and advances in exosome detection.展开更多
As one of the most common gynecological malignancies,peritoneal metastasis is a common feature and cause of high mortality in ovarian cancer(OC).Currently,the standard treatment for OC and its peritoneal metastasis is...As one of the most common gynecological malignancies,peritoneal metastasis is a common feature and cause of high mortality in ovarian cancer(OC).Currently,the standard treatment for OC and its peritoneal metastasis is maximal cytoreductive surgery(CRS)combined with platinum-based chemotherapy.Compared with intravenous chemotherapy,traditional intraperitoneal(IP)chemotherapy exhibits obvious pharmacokinetic(PK)advantages and systemic safety and has shown significant survival benefits in several clinical studies of OC patients.However,there remain several challenges in traditional IP chemotherapy,such as insufficient drug retention,a lack of tumor targeting,inadequate drug penetration,gastrointestinal toxicity,and limited inhibition of tumor metastasis and chemoresistance.Nanomedicine-based IP targeting delivery systems,through specific drug carrier design with tumor cells and tumor environment(TME)targeting,make it possible to overcome these challenges and maximize local therapy efficacy while reducing side effects.In this review article,the rationale and challenges of nanomedicine-based IP chemotherapies,as well as their in vivo fate after IP administration,which are crucial for their rational design and clinical translation,are firstly discussed.Then,current strategies for nanomedicine-based targeting delivery systems and the relevant clinical trials in IP chemotherapy are summarized.Finally,the future directions of the nanomedicine-based IP targeting delivery system for OC and its peritoneal metastasis are proposed,expecting to improve the clinical development of IP chemotherapy.展开更多
Ovarian cancer(OC),a common malignancy of the female reproductive system,has the highest mortality rate among gynecological cancers.A distinguishing feature of OC cells(OCCs)is their reduced autophagic flux compared w...Ovarian cancer(OC),a common malignancy of the female reproductive system,has the highest mortality rate among gynecological cancers.A distinguishing feature of OC cells(OCCs)is their reduced autophagic flux compared with normal cells.This phenomenon indicates that excessive autophagy activation or impaired autophagosome–lysosome fusion may lead to OCC death.This study investigated the anti-OC effects of dihydrotanshinone I(DHT),a tanshinone compound from Salvia miltiorrhiza.Proteomic analysis suggested that DHT suppressed OC growth via the autophagy–lysosome pathway,with sortilin 1(SORT1)identified as a critical target.In vitro,DHT promoted autophagosome formation mediated by microtubule-associated protein 1 light chain 3-II(LC3-II),while inhibiting autophagosome–lysosome fusion.The results of an orthotopic OC model corroborated these findings,showing that DHT induced autophagic cell death(ACD)and suppressed SORT1 expression in tumors.Further RNA interference experiments confirmed that SORT1 depletion caused autophagosomes to accumulate in OCCs.Notably,we found that SORT1 interacted with autophagy-related gene(ATG)-encoded proteins ATG5 and ATG16L1,and that depleting SORT1 increased the levels of these proteins.Co-immunoprecipitation,ubiquitination,and cellular thermal shift assay analyses revealed that DHT directly targeted and promoted ubiquitin-dependent degradation of SORT1.By degrading SORT1,ATG5 and ATG16L1 were released,which enhanced autophagosome formation and disrupted the autophagic flux.These findings identified DHT as a novel autophagosome inducer that induced ACD by targeting SORT1,making it a promising therapeutic candidate for OC.展开更多
In this descriptive review we look at the role of surgery for advanced ovarian cancer at other timepoints apart from the initial cytoreduction for front-line therapy or interval cytoreductive surgery after neoadjuvant...In this descriptive review we look at the role of surgery for advanced ovarian cancer at other timepoints apart from the initial cytoreduction for front-line therapy or interval cytoreductive surgery after neoadjuvant chemotherapy. The chief surgical problem to face after primary treatment is recurrent ovarian cancer. Of far more marginal concern are the second-look surgical procedures or the palliative efforts intended to resolve the patient's symptoms with no curative intent. The role of surgery in recurrent ovarian cancer remains poorly defi ned. Current data, albeit from non-randomized studies, nevertheless clearly support surgical cytoreduction in selected patients, a rarely curative expedient that invariably yields a marked survival advantage over chemotherapy alone. Despite these fi ndings, some consider it too early to adopt secondary cytoreduction as the standard care for patients with recurrent ovarian cancer and a randomized study is needed. Two ongoing randomized trials(Arbeitsgemeinschaft Gynkologische Onkologie-Desktop Ⅲ and Gynecologic Oncology Group 213) intend to verify the role of secondary cytoreduction for platinum-sensitive ovarian cancer compared with chemotherapy considered as standard care for these patients. We await the results of these two trials for a defi nitive answer to the matter.展开更多
Objectives:Ovarian cancer,a leading cause of gynecological malignancy-related mortality,is charac-terized by limited therapeutic options and a poor prognosis.Although pyrimethamine has emerged as a promising candidate...Objectives:Ovarian cancer,a leading cause of gynecological malignancy-related mortality,is charac-terized by limited therapeutic options and a poor prognosis.Although pyrimethamine has emerged as a promising candidate demonstrating efficacy in treating various tumors,the precise mechanisms of its antitumor effects remain obscure.This study was specifically designed to investigate the mode of action underlying the antitumor effects of pyrimethamine in preclinical settings.Methods:The effects of pyrimethamine on cellular proliferation were meticulously assessed using both the cell counting kit 8(CCK-8)assay and the colony formation assay,with the effects further confirmed in a murine model.A confocal microscope was utilized to monitor the dynamic alterations in mitochondria within ovarian cancer cells.Additionally,adenosine triphosphate(ATP)and reactive oxygen species(ROS)assays were conducted to measure mitochondrial damage induced by pyrimethamine in ovarian cancer cell lines.The mitochondrial membrane potential was assessed using fluorescent dyes as an indicator of mitochondrial functional status.Furthermore,transcriptome analysis and immunohistochemical techniques were employed to detect the impact of pyrimethamine on ovarian cancer cells.Results:Our results demonstrated that pyrimethamine induced ovarian cancer cell death through mitochondrial dysfunction and lethal mitophagy.Transcriptome profiling analysis and Western blot demonstrated that activation of the p38/JNK/ERK signaling pathway was implicated in the process of pyrimethamine-induced mitophagy in ovarian cancer cells.Importantly,combination treatment with pyrimethamine and paclitaxel in vitro and in vivo showed a synergistic antitumor effect.Conclusions:Altogether,these findings indicate that the antitumor effects of pyrimethamine result from the induction of lethal mitophagy via regulation of the p38/JNK/ERK pathway in ovarian cancer.Considering the low toxicity and high tolerance associated with pyrimethamine,it is suggested that pyrimethamine be evaluated in the treatment of ovarian cancer,either as a monotherapy or in combination with paclitaxel.展开更多
文摘Objective:To analyze the impact of nursing interventions based on quantitative assessment using the Kano model on the quality of rehabilitation in patients with early-stage ovarian cancer following laparoscopic radical surgery.Methods:A prospective clinical study was conducted involving 96 patients with newly diagnosed early-stage ovarian cancer who underwent laparoscopic radical surgery from December 2023 to December 2025.Patients were randomly assigned to groups using a random number table method before surgery.After surgery,the control group(n=48)received routine quantitative assessment nursing interventions,while the observation group(n=48)received nursing interventions based on quantitative assessment using the Kano model.Both groups received continuous nursing care until discharge.Differences between the groups were compared in terms of negative emotions,quality of life scores before and after postoperative intervention,postoperative recovery indicators,and nursing satisfaction evaluations on the day of discharge.Results:After intervention,the observation group had lower scores on the Self-Rating Anxiety Scale(SAS)and Self-Rating Depression Scale(SDS),as well as shorter recovery times for gastrointestinal function and food intake,and a shorter hospital stay compared to the control group.Additionally,the observation group had higher scores on the Quality-of-Life Instrument for Cancer Patients-Ovarian Cancer(QLICP-OV)than the control group,with statistically significant differences(p<0.05).The overall satisfaction with nursing care in the observation group was also higher than that in the control group,with a statistically significant difference(p<0.05).Conclusion:Implementing quantitative evaluation nursing interventions based on the Kano model for patients with early-stage ovarian cancer after laparoscopic radical surgery can,by addressing their postoperative basic health,disease awareness,and other intervention content needs to a comprehensive degree,actively promote postoperative recovery and improve their mental health and quality of life.
文摘Objective:Ovarian cancer(OC)ranks among the leading causes of mortality among the female cancers worldwide.Numerous studies have explored the development and progression of OC at multiple genetic regulatory levels.However,relatively few studies have explored the impact of post-translational modifications(PTM)on OC progression,which is essential for uncovering new therapeutic targets.This study aimed to systematically identify the key PTM types involved in OCprogression,and to explore and evaluate their translational potential as therapeutic targets.Methods:First,we utilized multiple general PTM antibodies to compare gross PTM levels between normal ovarian and OC tissues from clinical females.After identifying lactylation as the PTM with the most significant differences,we selected representative samples for label-free mass spectrometry to identify specific lactylation sites.Next,we transfected A2780(OC)cells with either wild-type(WT)or mutant(K192A[Q])poly(ADP-ribose)polymerase 1(PARP1)conjugated to enhanced green fluorescent protein(EGFP)with a StrepⅡpeptide tag and assessed various cellular indexes related to cell proliferation(clonogenicity assay),migration(scratch wound healing assay),and reactive oxygen species levels.Results:Pan-lactylation was significantly upregulated in clinical OC samples,with PARP1 lactylation at K192 being one of the most common modifications.The growth and migration of A2780 cells were markedly suppressed by overexpressing PARP1-WT but not mutant PARP1.Overexpressing PARP1 significantly downregulated the phosphorylation of extracellular signal-regulated kinases 1/2(ERK1/2).Conclusion:This study uncovered a novel PTM of PARP1 in OC,lactylation,and demonstrated that lactylation at K192 is crucial in regulating OC cell growth and migration via the ERK1/2 pathway.Further investigations are required to elucidate the broader functional implications of PARP1 lactylation and its therapeutic potential.
文摘Objectives:Monitoring of Cancer Antigen 125(CA125)during ovarian cancer(OC)maintenance treatment with poly(ADP-ribose)polymerase inhibitors(PARPis)may be insufficient when using Gynecologic Cancer Intergroup(GCIG)biochemical progression criteria.This study aimed to evaluate the usefulness of CA125 monitoring in detecting OC recurrence during PARPis maintenance treatment.Methods:This multicenter retrospective cohort study included patients with primary OC who achieved complete or partial response after first-line platinum-based chemotherapy followed by PARPis maintenance treatment.Progressionwas defined using Response EvaluationCriteria in Solid Tumors(RECIST)and GCIG biochemical criteria.New biochemical progression definitions,based on CA125 nadir determined using receiver operating characteristic(ROC)curve analysis,were proposed.Concordance between radiological and biochemical progression was assessed.Results:Of 142 patients,progression was detected in 54(38.03%)and 29(20.42%)using RECIST and GCIG criteria,respectively.The sensitivity,specificity,positive predictive value(PPV),and negative predictive value(NPV)of the GCIG criteria were 53.70%[95%confidence interval(CI):39.61%–67.38%],100.00%[95%CI:95.91%–100.00%],100.00%[95%CI:88.10%–100.00%]and 77.88%[95%CI:72.54%–82.43%],respectively.A cut-off of 1.59×nadir achieved 88.90%sensitivity and 87.20%specificity[Area Under Curve(AUC):91.10%,95%CI:84.70%–97.40%]with a false positive rate(FPR)of 12.67%.Defining biochemical progression as an increase in CA125 of≥3×nadir achieved sensitivity,specificity,PPV,NPV,and FPR of 79.63%[95%CI:66.47%–89.37%],98.86%[95%CI:93.83%–99.97%],97.73%[95%CI:85.91%–99.67%],88.78%[95%CI:82.35%–93.06%],and 1.14%,respectively.Diagnostic accuracy was higher using the≥3×nadir criterion compared with GCIG definition(91.55%vs.82.39%).Conclusion:GCIG biochemical progression criteria during PARPis maintenance treatment after first-line chemotherapymissed 46.3%of progressing patients.Anewcriterion—CA125≥3×nadir—improves sensitivity and NPV,while maintaining high specificity,offering a simple and practical approach for clinical implementation.
基金Supported by National Key Technology Research and Developmental Program of China,No.2022YFC2704400 and No.2022YFC2704405.
文摘BACKGROUND Mitochondrial genes are involved in tumor metabolism in ovarian cancer(OC)and affect immune cell infiltration and treatment responses.AIM To predict prognosis and immunotherapy response in patients diagnosed with OC using mitochondrial genes and neural networks.METHODS Prognosis,immunotherapy efficacy,and next-generation sequencing data of patients with OC were downloaded from The Cancer Genome Atlas and Gene Expression Omnibus.Mitochondrial genes were sourced from the MitoCarta3.0 database.The discovery cohort for model construction was created from 70% of the patients,whereas the remaining 30% constituted the validation cohort.Using the expression of mitochondrial genes as the predictor variable and based on neural network algorithm,the overall survival time and immunotherapy efficacy(complete or partial response)of patients were predicted.RESULTS In total,375 patients with OC were included to construct the prognostic model,and 26 patients were included to construct the immune efficacy model.The average area under the receiver operating characteristic curve of the prognostic model was 0.7268[95% confidence interval(CI):0.7258-0.7278]in the discovery cohort and 0.6475(95%CI:0.6466-0.6484)in the validation cohort.The average area under the receiver operating characteristic curve of the immunotherapy efficacy model was 0.9444(95%CI:0.8333-1.0000)in the discovery cohort and 0.9167(95%CI:0.6667-1.0000)in the validation cohort.CONCLUSION The application of mitochondrial genes and neural networks has the potential to predict prognosis and immunotherapy response in patients with OC,providing valuable insights into personalized treatment strategies.
文摘Paclitaxel is one of the commonly used drugs in postoperative chemotherapy for ovarian cancer patients. However, affected by drug dosage and individual differences in the course of medication, patients will have different degrees of adverse reactions, which will cause damage to the patient’s body once they occur. This paper retrospectively analyzed the clinical data of patients with severe allergic reactions such as fecal incontinence and numbness of hands and feet caused by the use of paclitaxel liposome during postoperative chemotherapy in a case of ovarian cancer admitted to our hospital. The causes and corresponding treatment measures were analyzed, in order to provide the reference for medical staff to take effective countermeasures in advance in the future.
文摘Following the publication,concerns have been raised about a number of figures in this article.The western blots in this article were presented with atypical,unusually shaped and possibly anomalous protein bands in many cases.
文摘Ovarian cancer ranks as the deadliest malignancy among female reproductive system cancers,posing a significant threat to women’s health.Around seven out of ten patients are diagnosed only after reaching progressive disease phases,a phenomenon closely linked to three key factors:the disease’s hidden onset location,lack of early symptoms,and absence of reliable early diagnostic methods.Therefore,identifying early diagnostic biomarkers and therapeutic targets is critical.Exosomes participate in various phases of ovarian tumorigenesis,including transforming normal cells into cancerous cells,immune regulation,invasion,metastasis,drug resistance,and angiogenesis,making them promising biomarkers for early ovarian cancer detection.This review summarizes current research on exosomal long non-coding RNAs(lncRNAs),miRNAs,and related proteins in ovarian cancer diagnosis.Exosome-based biomarkers have shown potential advantages,including high sensitivity,specificity,stability,and non-invasive accessibility.The study concludes that while exosomes hold significant diagnostic potential for ovarian cancer,additional investigations are required to standardize detection methods,validate clinical applicability,and elucidate underlying molecular mechanisms.
基金supported by Hubei Provincial Natural Science Foundation of China(No.2023AFB670).
文摘Ovarian cancer(OC),a highly lethal gynaecological malignancy,is often diagnosed at advanced stages,resulting in a poor prognosis.Sialylation,an important form of glycosylation,significantly contributes to the progression of various solid tumours,including OC.Aberrant sialylation promotes tumour progression and metastasis by altering the structure and function of glycoproteins.Although its role in several solid tumours is well documented,the role of abnormal sialylation in OC and its potential as a therapeutic target remain poorly understood.This review highlights sialylation as a key regulator of the progression,metastasis,and drug resistance of OC.A deeper understanding of altered sialylation can contribute to the identification of novel therapeutic strategies for OC.
基金funded by the Natural Science Foundation of Heilongjiang Province(No.LH2023H012)Postdoctoral Research Initiation Fund(No.LBH-Q20152)CAMS Innovation Fund for Medical Sciences(CIFMS,2019-I2M-5-078)。
文摘Ovarian cancer poses a significant threat to women's health,necessitating effective therapeutic strategies.Emd-D,an emodin derivative,demonstrates enhanced pharmaceutical properties and bioavailability.In this study,Cell Counting Kit 8(CCK8)assays and Ki-67 staining revealed dose-dependent inhibition of cell proliferation by Emd-D.Migration and invasion experiments confirmed its inhibitory effects on OVHM cells,while flow cytometry analysis demonstrated Emd-D-induced apoptosis.Mechanistic investigations elucidated that Emd-D functions as an inhibitor by directly binding to the glycolysis-related enzyme PFKFB4.This was corroborated by alterations in intracellular lactate and pyruvate levels,as well as glucose transporter 1(GLUT1)and hexokinase 2(HK2)expression.PFKFB4 overexpression experiments further supported the dependence of Emd-D on PFKFB4-mediated glycolysis and SRC3/mTORC1 pathway-associated apoptosis.In vivo experiments exhibited reduced xenograft tumor sizes upon Emd-D treatment,accompanied by suppressed glycolysis and increased expression of Bax/Bcl-2 apoptotic proteins within the tumors.In conclusion,our findings demonstrate Emd-D's potential as an anti-ovarian cancer agent through inhibition of the PFKFB4-dependent glycolysis pathway and induction of apoptosis.These results provide a foundation for further exploration of Emd-D as a promising drug candidate for ovarian cancer treatment.
基金Supported by the National Natural Science Foundation of China,No.81860716Natural Science Foundation of Gansu Province,No.22JR11RA237Fundamental Research Funds for the Central Universities of Northwest Minzu University,No.31920230067.
文摘BACKGROUND Substantial clinical evidence supports the efficacy of cognitive behavioral therapy(CBT)for various diseases,particularly in oncology.However,the true impact of CBT interventions on cancer-related fatigue and mental health in patients with ovarian cancer remains unknown.AIM To evaluate the effects of CBT on fatigue,anxiety,depression and quality of life in patients with ovarian cancer.METHODS Randomized controlled trials(RCTs)on CBT for patients with ovarian cancer were searched in the PubMed,EMBASE,Web of Science and Cochrane Library databases.According to the preferred reporting items for systematic reviews and meta-analyses statement,we formulated the inclusion and exclusion criteria,strictly screened the literatures,extracted data and performed a meta-analysis.RESULTS Six RCTs with 332 ovarian cancer patients were included.Compared with the control group,cancer fatigue[mean difference(MD)=-0.98,95%confidence interval(CI):-1.47 to-0.50],anxiety[standardized mean difference(SMD)=-0.64,95%CI:-0.91 to-0.36]and depression levels(SMD=-0.41,95%CI:-0.76 to-0.06)of the patients in the experimental group reduced after CBT intervention.Quality of life(MD=1.28,95%CI:0.65 to 1.90)and sleep quality(MD=-0.49,95%CI:-0.66 to-0.33)of the patients improved,and the differences between the groups were statistically significant(P<0.01).The quality evaluation results suggested that the quality of the included RCTs was low.The meta-regression results showed that patient age and nurse guidance affected treatment outcomes,especially anxiety,whereas the specific method of CBT had a non-significant effect.CONCLUSION CBT effectively improves mental status and cancer-related fatigue in patients with ovarian cancer undergoing chemotherapy.Future research should prioritize adequately powered RCTs with standardized outcome measures and longitudinal designs to establish sustained efficacy.
文摘c-Kit (CD117) is a type IIIa receptor tyrosine kinase (RTK) that plays a key role in regulating the normal physiological processes of cells. In addition, the activation of c-Kit activates the tyrosine kinase signal transduction pathway, which is closely related to the occurrence and development of gynecological tumors, especially ovarian cancer. This article reviews the mechanisms of platinum resistance in ovarian cancer and the research progress of c-Kit in ovarian cancer.
基金supported by the National Natural Science Foundation of China(Grant No.82274034)the Peking University Medicine plus X Pilot Program-Platform Construction Project(Grant No.2024YXXLHPT004).
文摘Ovarian cancer remains a leading cause of gynecological cancer mortality1,and patients with advanced stage ovarian cancer frequently develop malignant ascites that foster immunosuppressive microenvironments and therapeutic resistance2,3.Although ascites have traditionally been considered detrimental,we report a paradoxical role in which they enhance the cytotoxicity ofγδT cells—a unique T cell subset that can be allogenically transferred for cancer treatment4,5—toward ovarian cancer.
文摘BACKGROUND Ovarian carcinoma has the highest mortality rate among all gynecological cancers.Several reproductive and hormonal risk factors,including early menarche,late menopause,limited use of oral contraceptives,and a low pregnancy rate,have been identified as contributors to the increased susceptibility to ovarian cancer.Advancements in cancer therapy over the past century,including the emergence of precision oncology,underscore the importance of early detection and tailored interventions,factors particularly critical in ovarian cancer,where late-stage diagnosis remains a persistent barrier to survival.This challenge is compounded by the lack of a universally endorsed screening program,resulting in late-stage identification and widespread metastasis.AIM To evaluate demographic differences in ovarian cancer-related mortality from 1999 to 2020 among adult females aged≥25 years within the United States.METHODS Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database was used to collect de-identified death certificate data for malignant neoplasm of the ovaries related deaths in female adults aged 25 years and older from the year 1999 to 2020.Crude mortality rates and age-adjusted mortality rates(AAMRs)per 100000 people were calculated.Join point regression program was used to assess annual percent changes in mortality trends,with statistical significance set at P value<0.05.RESULTS Between 1999 and 2020,337619 deaths due to ovarian cancer occurred among United States females aged 25 to>85.The AAMR decreased from 14.62 in 1999 to 10.15 in 2020,with significant declines across various demographics.The AAMRs were highest among non-Hispanic White women,i.e.,13.53.Based on region,they were the highest in the Northeast(13.06)and Midwest(12.94).The steepest decline was observed in metropolitan areas as compared to nonmetropolitan ones.The study highlights significant progress in reducing ovarian cancer mortality across age,race/ethnicity,and geographic regions during this period.CONCLUSION The mortality trends for ovarian carcinoma patients showed an overall decrease,with the highest mortality rates observed among older individuals(65 to>85 years)and non-Hispanic Whites.These disparities underscore the need for equitable healthcare access and targeted policy interventions.
文摘BACKGROUND Ovarian cancer patients often face complex treatment processes and psychological challenges,with different treatment modalities potentially affecting patients’psychological adjustment abilities.AIM To explore the differences in psychological adjustment patterns among ovarian cancer patients receiving surgery,chemotherapy,targeted therapy,and combined therapy,and to analyze their relationship with clinical outcomes.METHODS A retrospective analysis was conducted on the clinical data of 286 ovarian cancer patients who received different treatment modalities from January 2020 to December 2023.Patients were divided into surgery group(n=78),chemotherapy group(n=65),targeted therapy group(n=61),and combined therapy group(n=82).The Self-Rating Anxiety Scale,Self-Rating Depression Scale,and Psychological Adjustment to Cancer Scale were used to assess psychological status,while quality of life,treatment adherence,and two-year survival rate data were collected.Some patients(n=76)received systematic psychological intervention,and the intervention effects were evaluated.RESULTS Patients in the combined therapy group had significantly higher Self-Rating Anxiety Scale(56.3±7.2)and Self-Rating Depression Scale(58.4±6.9)scores than other groups,with the highest incidence of anxiety(58.5%)and depression(62.2%);the targeted therapy group scored highest in the positive coping dimension(28.5±3.6)and had the lowest incidence of anxiety and depression(29.5%/31.1%).Logistic regression analysis showed that positive coping(odds ratio=2.86,95%confidence interval:1.75-4.68)and utilization of social support(odds ratio=2.13,95%confidence interval:1.42-3.56)were protective factors for good treatment adherence.Longitudinal assessment showed that although all patients experienced increased anxiety and depression symptoms at 3 months of treatment,the targeted therapy group and surgery group showed significant improvement at 6 months(P<0.05),while the combined therapy group showed no significant improvement.Psychological intervention effectively improved patients’treatment adherence(by 22.7%)and quality of life(by 15.6 points),with the best effect in the combined therapy group(anxiety incidence decreased by 30.5%,P<0.001).CONCLUSION Different treatment modalities significantly affect the psychological adjustment abilities of ovarian cancer patients,with combined therapy patients facing greater psychological challenges,while targeted therapy patients exhibit healthier psychological adjustment patterns.
基金supported by the National Natural Science Foundation of China(82001846)the 345 Talent Project of Shengjing Hospital of China Medical University.
文摘Ovarian cancer(OC)remains one of the most lethal gynecological malignancies globally.Despite the implementation of various medical imaging approaches for OC screening,achieving accurate differential diagnosis of ovarian tumors continues to pose significant challenges due to variability in image performance,resulting in a lack of objectivity that relies heavily on the expertise of medical professionals.This challenge can be addressed through the emergence and advancement of radiomics,which enables high-throughput extraction of valuable information from conventional medical images.Furthermore,radiomics can integrate with genomics,a novel approach termed radiogenomics,which allows for a more comprehensive,precise,and personalized assessment of tumor biological features.In this review,we present an extensive overview of the application of radiomics and radiogenomics in diagnosing and predicting ovarian tumors.The findings indicate that artificial intelligence methods based on imaging can accurately differentiate between benign and malignant ovarian tumors,as well as classify their subtypes.Moreover,these methods are effective in forecasting survival rates,treatment outcomes,metastasis risk,and recurrence for patients with OC.It is anticipated that these advancements will function as decision-support tools for managing OC while contributing to the advancement of precision medicine.
基金Special thanks go to the National Natural Science Foundation for Youth,China(Grant No.:82202648)the Introduce High-Level Talent Incentive Project,China(Grant No.:0103-31021200052)for their financial support,which made this work possible.
文摘Ovarian cancer is a prevalent gynecological malignancy with high mortality and low survival rates.The absence of specific symptoms in early stages often leads to late-stage diagnoses.Standard treatment typically includes surgery followed by platinum and paclitaxel chemotherapy.Exosomes,nanoscale vesicles released by various cell types,are key in intercellular communication,carrying biologically active molecules like proteins,lipids,enzymes,mRNA,and miRNAs.They are involved in tumor microenvironment remodeling,angiogenesis,metastasis,and chemoresistance in ovarian cancer.Emerging research highlights exosomes as drug carriers and therapeutic targets to suppress anti-tumor immune responses.Surface-enhanced Raman scattering(SERS)enables multiplexed,sensitive,and rapid detection of exosome surface proteins,offering advantages such as low background noise,no photobleaching,robustness,and high sensitivity over other detection methods.This review explores the relationship between exosomes and chemoresistance in ovarian cancer,examining the mechanisms by which exosomes contribute to drug resistance and their clinical implications.The goal is to provide new insights into chemoresistance mechanisms,improve diagnosis and intervention strategies,and enhance chemotherapy sensitivity in clinical treatments.In addition,the prospects of exosomes as drug carriers to resist chemical resistance and improve the survival of ovarian cancer patients are summarized.This article emphasizes the role of SERS in detecting ovarian cancer exosomes and advances in exosome detection.
基金supported by the National Key R&D Program of China(No.2020YFE0201700)the Liaoning Revitalization Talents Program(No.XLYC1908031)。
文摘As one of the most common gynecological malignancies,peritoneal metastasis is a common feature and cause of high mortality in ovarian cancer(OC).Currently,the standard treatment for OC and its peritoneal metastasis is maximal cytoreductive surgery(CRS)combined with platinum-based chemotherapy.Compared with intravenous chemotherapy,traditional intraperitoneal(IP)chemotherapy exhibits obvious pharmacokinetic(PK)advantages and systemic safety and has shown significant survival benefits in several clinical studies of OC patients.However,there remain several challenges in traditional IP chemotherapy,such as insufficient drug retention,a lack of tumor targeting,inadequate drug penetration,gastrointestinal toxicity,and limited inhibition of tumor metastasis and chemoresistance.Nanomedicine-based IP targeting delivery systems,through specific drug carrier design with tumor cells and tumor environment(TME)targeting,make it possible to overcome these challenges and maximize local therapy efficacy while reducing side effects.In this review article,the rationale and challenges of nanomedicine-based IP chemotherapies,as well as their in vivo fate after IP administration,which are crucial for their rational design and clinical translation,are firstly discussed.Then,current strategies for nanomedicine-based targeting delivery systems and the relevant clinical trials in IP chemotherapy are summarized.Finally,the future directions of the nanomedicine-based IP targeting delivery system for OC and its peritoneal metastasis are proposed,expecting to improve the clinical development of IP chemotherapy.
基金supported by the National Key Research and Development Program of China(2023YFC3503900)the National Natural Science Foundation of China(82305001)+3 种基金the Zhejiang Provincial Natural Science Foundation of China(LQ24H280011)the Science Research Fund of Administration of Traditional Chinese Medicine of Zhejiang Province(2023ZR014)the National Young Qihuang Scholars Training Programthe Research Project of Zhejiang Chinese Medical University(2022RCZXZK18,2023JKZKTS17)。
文摘Ovarian cancer(OC),a common malignancy of the female reproductive system,has the highest mortality rate among gynecological cancers.A distinguishing feature of OC cells(OCCs)is their reduced autophagic flux compared with normal cells.This phenomenon indicates that excessive autophagy activation or impaired autophagosome–lysosome fusion may lead to OCC death.This study investigated the anti-OC effects of dihydrotanshinone I(DHT),a tanshinone compound from Salvia miltiorrhiza.Proteomic analysis suggested that DHT suppressed OC growth via the autophagy–lysosome pathway,with sortilin 1(SORT1)identified as a critical target.In vitro,DHT promoted autophagosome formation mediated by microtubule-associated protein 1 light chain 3-II(LC3-II),while inhibiting autophagosome–lysosome fusion.The results of an orthotopic OC model corroborated these findings,showing that DHT induced autophagic cell death(ACD)and suppressed SORT1 expression in tumors.Further RNA interference experiments confirmed that SORT1 depletion caused autophagosomes to accumulate in OCCs.Notably,we found that SORT1 interacted with autophagy-related gene(ATG)-encoded proteins ATG5 and ATG16L1,and that depleting SORT1 increased the levels of these proteins.Co-immunoprecipitation,ubiquitination,and cellular thermal shift assay analyses revealed that DHT directly targeted and promoted ubiquitin-dependent degradation of SORT1.By degrading SORT1,ATG5 and ATG16L1 were released,which enhanced autophagosome formation and disrupted the autophagic flux.These findings identified DHT as a novel autophagosome inducer that induced ACD by targeting SORT1,making it a promising therapeutic candidate for OC.
文摘In this descriptive review we look at the role of surgery for advanced ovarian cancer at other timepoints apart from the initial cytoreduction for front-line therapy or interval cytoreductive surgery after neoadjuvant chemotherapy. The chief surgical problem to face after primary treatment is recurrent ovarian cancer. Of far more marginal concern are the second-look surgical procedures or the palliative efforts intended to resolve the patient's symptoms with no curative intent. The role of surgery in recurrent ovarian cancer remains poorly defi ned. Current data, albeit from non-randomized studies, nevertheless clearly support surgical cytoreduction in selected patients, a rarely curative expedient that invariably yields a marked survival advantage over chemotherapy alone. Despite these fi ndings, some consider it too early to adopt secondary cytoreduction as the standard care for patients with recurrent ovarian cancer and a randomized study is needed. Two ongoing randomized trials(Arbeitsgemeinschaft Gynkologische Onkologie-Desktop Ⅲ and Gynecologic Oncology Group 213) intend to verify the role of secondary cytoreduction for platinum-sensitive ovarian cancer compared with chemotherapy considered as standard care for these patients. We await the results of these two trials for a defi nitive answer to the matter.
基金supported by the Natural Science Foundation of Sichuan Province,China,grant number:2021YJ0011.
文摘Objectives:Ovarian cancer,a leading cause of gynecological malignancy-related mortality,is charac-terized by limited therapeutic options and a poor prognosis.Although pyrimethamine has emerged as a promising candidate demonstrating efficacy in treating various tumors,the precise mechanisms of its antitumor effects remain obscure.This study was specifically designed to investigate the mode of action underlying the antitumor effects of pyrimethamine in preclinical settings.Methods:The effects of pyrimethamine on cellular proliferation were meticulously assessed using both the cell counting kit 8(CCK-8)assay and the colony formation assay,with the effects further confirmed in a murine model.A confocal microscope was utilized to monitor the dynamic alterations in mitochondria within ovarian cancer cells.Additionally,adenosine triphosphate(ATP)and reactive oxygen species(ROS)assays were conducted to measure mitochondrial damage induced by pyrimethamine in ovarian cancer cell lines.The mitochondrial membrane potential was assessed using fluorescent dyes as an indicator of mitochondrial functional status.Furthermore,transcriptome analysis and immunohistochemical techniques were employed to detect the impact of pyrimethamine on ovarian cancer cells.Results:Our results demonstrated that pyrimethamine induced ovarian cancer cell death through mitochondrial dysfunction and lethal mitophagy.Transcriptome profiling analysis and Western blot demonstrated that activation of the p38/JNK/ERK signaling pathway was implicated in the process of pyrimethamine-induced mitophagy in ovarian cancer cells.Importantly,combination treatment with pyrimethamine and paclitaxel in vitro and in vivo showed a synergistic antitumor effect.Conclusions:Altogether,these findings indicate that the antitumor effects of pyrimethamine result from the induction of lethal mitophagy via regulation of the p38/JNK/ERK pathway in ovarian cancer.Considering the low toxicity and high tolerance associated with pyrimethamine,it is suggested that pyrimethamine be evaluated in the treatment of ovarian cancer,either as a monotherapy or in combination with paclitaxel.
